Form 4: Spruce Biosciences CFO Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
Spruce Biosciences' CFO, Samir M. Gharib, reports the vesting and subsequent transactions of restricted stock units (RSUs), resulting in changes to his beneficial ownership of company stock.
Summary
- Samir M. Gharib, the President and CFO of Spruce Biosciences, reported transactions related to the vesting of restricted stock units (RSUs).
- On December 10, 2024, 154,000 performance-based RSUs vested, and 54,948 shares were withheld for taxes.
- On December 16, 2024, 38,500 time-based RSUs vested, and 13,737 shares were withheld for taxes.
- Also on December 16, 2024, 37,250 time-based RSUs vested, and 13,291 shares were withheld for taxes.
- These transactions resulted in a net increase of 154,000 shares from the performance based RSUs and a net increase of 48,722 shares from the time based RSUs, after accounting for shares withheld for taxes.
- The reported transactions changed Mr. Gharib's direct ownership of Spruce Biosciences common stock.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative news. The vesting of performance based RSUs is a positive sign.
Positives
- The vesting of performance-based RSUs indicates that certain performance goals were met by the company.
- The vesting of time-based RSUs is part of the standard compensation package for the CFO.
Industry Context
This is a standard SEC Form 4 filing, which is common for company insiders who have transactions involving company stock, particularly after vesting of equity awards.
Comparison to Industry Standards
- The vesting of RSUs is a common practice in the biotechnology industry as part of executive compensation packages.
- Many companies in the biotech sector use a combination of performance-based and time-based vesting schedules for equity awards.
- The tax withholding of shares upon vesting is also a standard practice to cover the tax liabilities of the employee.
Stakeholder Impact
- The transactions increase the number of shares held by the CFO, aligning his interests with those of shareholders.
- The vesting of performance-based RSUs may be viewed positively by shareholders as it indicates the achievement of company goals.
Key Dates
| Date | Description |
|---|---|
| 2022-12-05 | Date of grant of 149,000 time-based RSUs to the Reporting Person. |
| 2023-12-14 | Date of grant of 308,000 RSUs to the Reporting Person. |
| 2023-12-15 | First annual vesting date for the 149,000 time-based RSUs. |
| 2024-12-10 | Date of vesting of 154,000 performance-based RSUs. |
| 2024-12-15 | Date of vesting of 38,500 time-based RSUs. |
| 2024-12-16 | Date of vesting of 37,250 time-based RSUs. |
| 2024-12-20 | Date of signature of the Form 4. |
Keywords
RSU, Restricted Stock Units, Form 4, Beneficial Ownership, Insider Trading, Spruce Biosciences, SPRB, Samir Gharib, CFO, Stock Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.